Evidence map›Paper›PMID 27080322›Full record

Trial reportMolecular imaging and biology2016

PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.

Steven P Rowe, Katarzyna J Macura, Esther Mena, Amanda L Blackford, Rosa Nadal, Emmanuel S Antonarakis, Mario Eisenberger, Michael Carducci, Hong Fan, Robert F Dannals and 5 more

3 registry-linked trialsOpen access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Molecular imaging and biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 132 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed, 1 pooled it
22.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03585114 phase2active not recruitingnot on this mapstarted 2018, after this paper: background citation

Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers

TypeinterventionalSponsorColumbia UniversityRan2018 to 2022Enrolled11ConditionsMetastatic Prostate CancerArms[F-18] DCFPyL, PET/CT imaging
NCT04266392 early_phase1completednot on this mapstarted 2019, after this paper: background citation

Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand

TypeinterventionalSponsorStony Brook UniversityRan2019 to 2021Enrolled20ConditionsProstate CancerArms[18F]-DCFPyl Ligand
NCT05936658 phase3active not recruitingnot on this mapstarted 2023, after this paper: background citation

A Multi-center, Open-label, Single Arm Phase III Clinical Trial for the Diagnostic Efficacy Assessment and Safety Evaluation by [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer

TypeinterventionalSponsorFutureChemRan2023 to 2025Enrolled138ConditionsHigh Risk Prostate CarcinomaArms[F-18]Florastamin
3 · Its place in the literature

Who cites it

132 citing papers in PubMed, 1 synthesis or guideline pooled it, 256 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. AnCurrent radiopharmaceuticals · 2024
    Trial
  4. [European journal of nuclear medicine and molecular imaging · 2023
    Trial
  5. Radiology · 2022
    Trial
  6. Diagnostic Performance ofClinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Trial
  7. Exploratory cost-effectiveness analysis ofClinical & experimental metastasis · 2020
    Trial
  8. Prospective Comparison of PET Imaging with PSMA-TargetedJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020
    Trial
  9. Trial
  10. A Prospective Study onJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Trial
  11. Quantitative Assessment of Early [Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017
    Trial
  12. Article
  13. Article
  14. Article
  15. Review
  16. International journal of clinical oncology · 2026
    Article
  17. Article
  18. Article
  19. Review
  20. Article

72 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Steven P RoweThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Katarzyna J MacuraThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Esther MenaThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Amanda L BlackfordDepartment of Oncology in the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Rosa NadalDepartment of Oncology in the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Emmanuel S AntonarakisDepartment of Oncology in the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Mario EisenbergerDepartment of Oncology in the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Michael CarducciDepartment of Oncology in the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Hong FanThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Robert F DannalsThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Ying ChenThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Ronnie C MeaseThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Zsolt SzaboThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Martin G PomperThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Steve Y ChoThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD, USA. scho@uwhealth.org.
Johns Hopkins University · USSidney Kimmel Comprehensive Cancer Center · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Theranostic Imaging of Metastatic Prostate CancerP50CA103175 · NCI · JOHNS HOPKINS UNIVERSITY · PI BARKER, PETER B · 2003 to 2015
$17.9M
PSMA-based Cancer Imaging AgentsR01CA134675 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI POMPER, MARTIN G · 2009 to 2025
$6.2M
PSMA Directed Imaging of Prostate Cancer Focus on Androgen Receptor DynamicsU01CA183031 · NCI · JOHNS HOPKINS UNIVERSITY · PI DEWEESE, THEODORE L, POMPER, MARTIN G · 2015 to 2017
$1.2M
Social Determinants of Breast Cancer SurvivorshipK01CA184288 · NCI · UNIVERSITY OF PENNSYLVANIA · PI DEAN, LORRAINE TIERA · 2014 to 2018
$767k
NCI NIH HHS K01 CA184288NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA103175NCI NIH HHS R01 CA134675NCI NIH HHS U01 CA183031
6 · The paper itself

Abstract

purposeCurrent standard of care conventional imaging modalities (CIM) such as X-ray computed tomography (CT) and bone scan can be limited for detection of metastatic prostate cancer and therefore improved imaging methods are an unmet clinical need. We evaluated the utility of a novel second-generation low molecular weight radiofluorinated prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) radiotracer, [(18)F]DCFPyL, in patients with metastatic prostate cancer. PROCEDURES: Nine patients with suspected prostate cancer recurrence, eight with CIM evidence of metastatic prostate cancer and one with biochemical recurrence, were imaged with [(18)F]DCFPyL PET/CT. Eight of the patients had contemporaneous CIM for comparison. A lesion-by-lesion comparison of the detection of suspected sites of metastatic prostate cancer was carried out between PET and CIM. Statistical analysis for estimated proportions of inter-modality agreement for detection of metastatic disease was calculated accounting for intra-patient correlation using general estimating equation (GEE) intercept-only regression models.

resultsOne hundred thirty-nine sites of PET positive [(18)F]DCFPyL uptake (138 definite, 1 equivocal) for metastatic disease were detected in the eight patients with available comparison CIM. By contrast, only 45 lesions were identified on CIM (30 definite, 15 equivocal). When lesions were negative or equivocal on CIM, it was estimated that a large portion of these lesions or 0.72 (95 % confidence interval (CI) 0.55-0.84) would be positive on [(18)F]DCFPyL PET. Conversely, of those lesions negative or equivocal on [(18)F]DCFPyL PET, it was estimated that only a very small proportion or 0.03 (95 % CI 0.01-0.07) would be positive on CIM. Delayed 2-h-post-injection time point PET yielded higher tumor radiotracer uptake and higher tumor-to-background ratios than an earlier 1-h-post-injection time point.

conclusionsA novel PSMA-targeted PET radiotracer, [(18)F]DCFPyL, was able to a large number of suspected sites of prostate cancer, many of which were occult or equivocal by CIM. This study provides strong preliminary evidence for the use of this second-generation PSMA-targeted PET radiotracer for detection of metastatic prostate cancer and lends further support for the importance of PSMA-targeted PET imaging in prostate cancer.

Indexed as

AgedAged, 80 and overDemographyHumansLysineMaleMiddle AgedPositron Emission Tomography Computed TomographyProstate-Specific AntigenProstatic NeoplasmsRegression AnalysisUreaWhole Body Imaging2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acidLysineProstate-Specific AntigenUrea[18F]DCFPyLBone scanComputed tomography (CT)Metastatic prostate cancerPET/CTProstate-specific membrane antigen (PSMA)

Identifiers

PMID27080322
PMCPMC5261857
OpenAlexW2468071338

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.